APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Antibody Expression Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Antibody Expression Service Market Outlook and Growth Opportunities 2026

4 July 2026217 pages

Choose your research edition.

Industry ResearchRecombinant Antibody Expression Service Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Antibody Expression Service Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Recombinant Antibody Expression Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Antibody Expression Service Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Antibody Expression Service Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Recombinant Antibody Expression Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Antibody Expression Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Antibody Expression Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Antibody Expression Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Antibody Expression Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Antibody Expression Service market include GenScript Biotech, Creative Biolabs, Thermo Fisher Scientific, Bio-Rad Laboratories, Sino Biological, ProMab Biotechnologies, LakePharma(Curia), Profacgen and Atlas Antibodies, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Recombinant Antibody Expression Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Antibody Expression Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Antibody Expression Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Recombinant Antibody Expression Service market.

Recombinant Antibody Expression Service Segment by Company

GenScript Biotech

Creative Biolabs

Thermo Fisher Scientific

Bio-Rad Laboratories

Sino Biological

ProMab Biotechnologies

LakePharma(Curia)

Profacgen

Atlas Antibodies

Absolute Antibody

ProteoGenix

Rockland Immunochemicals

Proteintech

RayBiotech

BioLegend

Agilent Technologies

Novus Biologicals

OriGene Technologies

ACROBiosystems

Fitzgerald Industries(Biosynth)

Azenta Life Sciences

R&D Systems

Abnova

WuXi Biologics

Biointron Biological

Detai Bio-Tech

cusabio

FITGENE

GentleGen

TekBiotech

Recombinant Antibody Expression Service Segment by Type

Recombinant Protein Mammalian Expression Service

Chimeric Antibody Expression Service

Recombinant Fragment Antibody Expression Service

VHH Nanobody Expression Service

Recombinant Antibody Expression Service Segment by Application

Scientific Research

Immunodiagnostics

Antibody Drug Development

Others

Recombinant Antibody Expression Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Antibody Expression Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Recombinant Antibody Expression Service key companies, revenue, market share, and recent developments.

3. To split the Recombinant Antibody Expression Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Recombinant Antibody Expression Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Antibody Expression Service significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Antibody Expression Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Antibody Expression Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Antibody Expression Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Antibody Expression Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Antibody Expression Service industry.

Chapter 3: Detailed analysis of Recombinant Antibody Expression Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Recombinant Antibody Expression Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Recombinant Antibody Expression Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Antibody Expression Service Industry Trends Table 2. Recombinant Antibody Expression Service Industry Drivers Table 3. Recombinant Antibody Expression Service Industry Opportunities and Challenges Table 4. Recombinant Antibody Expression Service Industry Restraints Table 5. Global Recombinant Antibody Expression Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Antibody Expression Service Revenue Share by Company (2021-2026) Table 7. Global Recombinant Antibody Expression Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Recombinant Antibody Expression Service Key Company Manufacturing Base & Headquarters Table 9. Global Recombinant Antibody Expression Service Company, Product Type & Application Table 10. Global Recombinant Antibody Expression Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Recombinant Antibody Expression Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Recombinant Protein Mammalian Expression Service Table 15. Significant Companies of Chimeric Antibody Expression Service Table 16. Significant Companies of Recombinant Fragment Antibody Expression Service Table 17. Significant Companies of VHH Nanobody Expression Service Table 18. Global Recombinant Antibody Expression Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Recombinant Antibody Expression Service Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Recombinant Antibody Expression Service Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Recombinant Antibody Expression Service Sales Value Share by Type (2021-2026) Table 22. Global Recombinant Antibody Expression Service Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Scientific Research Table 24. Significant Companies of Immunodiagnostics Table 25. Significant Companies of Antibody Drug Development Table 26. Significant Companies of Others Table 27. Global Recombinant Antibody Expression Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Recombinant Antibody Expression Service Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Recombinant Antibody Expression Service Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Recombinant Antibody Expression Service Sales Value Share by Application (2021-2026) Table 31. Global Recombinant Antibody Expression Service Sales Value Share by Application (2027-2032) Table 32. Global Recombinant Antibody Expression Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Recombinant Antibody Expression Service Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Recombinant Antibody Expression Service Sales Value Share by Region (2021-2026) Table 35. Global Recombinant Antibody Expression Service Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Recombinant Antibody Expression Service Sales Value Share by Region (2027-2032) Table 37. Global Recombinant Antibody Expression Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Recombinant Antibody Expression Service Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Recombinant Antibody Expression Service Sales Value Market Share by Country (2021-2026) Table 40. Global Recombinant Antibody Expression Service Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Recombinant Antibody Expression Service Sales Value Market Share by Country (2027-2032) Table 42. GenScript Biotech Company Information Table 43. GenScript Biotech Business Overview Table 44. GenScript Biotech Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. GenScript Biotech Recombinant Antibody Expression Service Product Portfolio Table 46. GenScript Biotech Recent Development Table 47. Creative Biolabs Company Information Table 48. Creative Biolabs Business Overview Table 49. Creative Biolabs Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Creative Biolabs Recombinant Antibody Expression Service Product Portfolio Table 51. Creative Biolabs Recent Development Table 52. Thermo Fisher Scientific Company Information Table 53. Thermo Fisher Scientific Business Overview Table 54. Thermo Fisher Scientific Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Thermo Fisher Scientific Recombinant Antibody Expression Service Product Portfolio Table 56. Thermo Fisher Scientific Recent Development Table 57. Bio-Rad Laboratories Company Information Table 58. Bio-Rad Laboratories Business Overview Table 59. Bio-Rad Laboratories Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Bio-Rad Laboratories Recombinant Antibody Expression Service Product Portfolio Table 61. Bio-Rad Laboratories Recent Development Table 62. Sino Biological Company Information Table 63. Sino Biological Business Overview Table 64. Sino Biological Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sino Biological Recombinant Antibody Expression Service Product Portfolio Table 66. Sino Biological Recent Development Table 67. ProMab Biotechnologies Company Information Table 68. ProMab Biotechnologies Business Overview Table 69. ProMab Biotechnologies Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. ProMab Biotechnologies Recombinant Antibody Expression Service Product Portfolio Table 71. ProMab Biotechnologies Recent Development Table 72. LakePharma(Curia) Company Information Table 73. LakePharma(Curia) Business Overview Table 74. LakePharma(Curia) Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. LakePharma(Curia) Recombinant Antibody Expression Service Product Portfolio Table 76. LakePharma(Curia) Recent Development Table 77. Profacgen Company Information Table 78. Profacgen Business Overview Table 79. Profacgen Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Profacgen Recombinant Antibody Expression Service Product Portfolio Table 81. Profacgen Recent Development Table 82. Atlas Antibodies Company Information Table 83. Atlas Antibodies Business Overview Table 84. Atlas Antibodies Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Atlas Antibodies Recombinant Antibody Expression Service Product Portfolio Table 86. Atlas Antibodies Recent Development Table 87. Absolute Antibody Company Information Table 88. Absolute Antibody Business Overview Table 89. Absolute Antibody Recombinant Antibody Expression Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Absolute Antibody Recombinant Antibody Expression Service Product Portfolio Table 91. Absolute Antibody Recent Development Table 92. ProteoGenix Company Information Table 93. ProteoGenix Business Overview Table 94. ProteoGenix Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. ProteoGenix Recombinant Antibody Expression Service Product Portfolio Table 96. ProteoGenix Recent Development Table 97. Rockland Immunochemicals Company Information Table 98. Rockland Immunochemicals Business Overview Table 99. Rockland Immunochemicals Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Rockland Immunochemicals Recombinant Antibody Expression Service Product Portfolio Table 101. Rockland Immunochemicals Recent Development Table 102. Proteintech Company Information Table 103. Proteintech Business Overview Table 104. Proteintech Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Proteintech Recombinant Antibody Expression Service Product Portfolio Table 106. Proteintech Recent Development Table 107. RayBiotech Company Information Table 108. RayBiotech Business Overview Table 109. RayBiotech Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. RayBiotech Recombinant Antibody Expression Service Product Portfolio Table 111. RayBiotech Recent Development Table 112. BioLegend Company Information Table 113. BioLegend Business Overview Table 114. BioLegend Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. BioLegend Recombinant Antibody Expression Service Product Portfolio Table 116. BioLegend Recent Development Table 117. Agilent Technologies Company Information Table 118. Agilent Technologies Business Overview Table 119. Agilent Technologies Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Agilent Technologies Recombinant Antibody Expression Service Product Portfolio Table 121. Agilent Technologies Recent Development Table 122. Novus Biologicals Company Information Table 123. Novus Biologicals Business Overview Table 124. Novus Biologicals Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Novus Biologicals Recombinant Antibody Expression Service Product Portfolio Table 126. Novus Biologicals Recent Development Table 127. OriGene Technologies Company Information Table 128. OriGene Technologies Business Overview Table 129. OriGene Technologies Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. OriGene Technologies Recombinant Antibody Expression Service Product Portfolio Table 131. OriGene Technologies Recent Development Table 132. ACROBiosystems Company Information Table 133. ACROBiosystems Business Overview Table 134. ACROBiosystems Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. ACROBiosystems Recombinant Antibody Expression Service Product Portfolio Table 136. ACROBiosystems Recent Development Table 137. Fitzgerald Industries(Biosynth) Company Information Table 138. Fitzgerald Industries(Biosynth) Business Overview Table 139. Fitzgerald Industries(Biosynth) Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 140. Fitzgerald Industries(Biosynth) Recombinant Antibody Expression Service Product Portfolio Table 141. Fitzgerald Industries(Biosynth) Recent Development Table 142. Azenta Life Sciences Company Information Table 143. Azenta Life Sciences Business Overview Table 144. Azenta Life Sciences Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 145. Azenta Life Sciences Recombinant Antibody Expression Service Product Portfolio Table 146. Azenta Life Sciences Recent Development Table 147. R&D Systems Company Information Table 148. R&D Systems Business Overview Table 149. R&D Systems Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 150. R&D Systems Recombinant Antibody Expression Service Product Portfolio Table 151. R&D Systems Recent Development Table 152. Abnova Company Information Table 153. Abnova Business Overview Table 154. Abnova Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 155. Abnova Recombinant Antibody Expression Service Product Portfolio Table 156. Abnova Recent Development Table 157. WuXi Biologics Company Information Table 158. WuXi Biologics Business Overview Table 159. WuXi Biologics Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 160. WuXi Biologics Recombinant Antibody Expression Service Product Portfolio Table 161. WuXi Biologics Recent Development Table 162. Biointron Biological Company Information Table 163. Biointron Biological Business Overview Table 164. Biointron Biological Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 165. Biointron Biological Recombinant Antibody Expression Service Product Portfolio Table 166. Biointron Biological Recent Development Table 167. Detai Bio-Tech Company Information Table 168. Detai Bio-Tech Business Overview Table 169. Detai Bio-Tech Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 170. Detai Bio-Tech Recombinant Antibody Expression Service Product Portfolio Table 171. Detai Bio-Tech Recent Development Table 172. cusabio Company Information Table 173. cusabio Business Overview Table 174. cusabio Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 175. cusabio Recombinant Antibody Expression Service Product Portfolio Table 176. cusabio Recent Development Table 177. FITGENE Company Information Table 178. FITGENE Business Overview Table 179. FITGENE Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 180. FITGENE Recombinant Antibody Expression Service Product Portfolio Table 181. FITGENE Recent Development Table 182. GentleGen Company Information Table 183. GentleGen Business Overview Table 184. GentleGen Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 185. GentleGen Recombinant Antibody Expression Service Product Portfolio Table 186. GentleGen Recent Development Table 187. TekBiotech Company Information Table 188. TekBiotech Business Overview Table 189. TekBiotech Recombinant Antibody Expression Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 190. TekBiotech Recombinant Antibody Expression Service Product Portfolio Table 191. TekBiotech Recent Development Table 192. Research Programs/Design for This Report Table 193. Authors List of This Report Table 194. Secondary Sources Table 195. Primary Sources List of Figures Figure 1. Recombinant Antibody Expression Service Product Image Figure 2. Global Recombinant Antibody Expression Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Antibody Expression Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Antibody Expression Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Recombinant Protein Mammalian Expression Service Image Figure 8. Chimeric Antibody Expression Service Image Figure 9. Recombinant Fragment Antibody Expression Service Image Figure 10. VHH Nanobody Expression Service Image Figure 11. Global Recombinant Antibody Expression Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Recombinant Antibody Expression Service Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Recombinant Antibody Expression Service Sales Value Share by Type (2021-2032) Figure 14. Scientific Research Image Figure 15. Immunodiagnostics Image Figure 16. Antibody Drug Development Image Figure 17. Others Image Figure 18. Global Recombinant Antibody Expression Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Recombinant Antibody Expression Service Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Recombinant Antibody Expression Service Sales Value Share by Application (2021-2032) Figure 21. Global Recombinant Antibody Expression Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Recombinant Antibody Expression Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Recombinant Antibody Expression Service Sales Value (2021-2032) & (US$ Million) Figure 24. North America Recombinant Antibody Expression Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Recombinant Antibody Expression Service Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Recombinant Antibody Expression Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Recombinant Antibody Expression Service Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Recombinant Antibody Expression Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Recombinant Antibody Expression Service Sales Value (2021-2032) & (US$ Million) Figure 30. South America Recombinant Antibody Expression Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Recombinant Antibody Expression Service Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Recombinant Antibody Expression Service Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Protein Mammalian Expression Service
  • Chimeric Antibody Expression Service
  • Recombinant Fragment Antibody Expression Service
  • VHH Nanobody Expression Service
Applications
  • Scientific Research
  • Immunodiagnostics
  • Antibody Drug Development
  • Others
Companies covered
  • GenScript Biotech
  • Creative Biolabs
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Sino Biological
  • ProMab Biotechnologies
  • LakePharma(Curia)
  • Profacgen
  • Atlas Antibodies
  • Absolute Antibody
  • ProteoGenix
  • Rockland Immunochemicals
  • Proteintech
  • RayBiotech
  • BioLegend
  • Agilent Technologies
  • Novus Biologicals
  • OriGene Technologies
  • ACROBiosystems
  • Fitzgerald Industries(Biosynth)
  • Azenta Life Sciences
  • R&D Systems
  • Abnova
  • WuXi Biologics
  • Biointron Biological
  • Detai Bio-Tech
  • cusabio
  • FITGENE
  • GentleGen
  • TekBiotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Antibody Expression Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Antibody Expression Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Recombinant Antibody Expression Service Market Dynamics
  1. 2.1 Recombinant Antibody Expression Service Industry Trends
  2. 2.2 Recombinant Antibody Expression Service Industry Drivers
  3. 2.3 Recombinant Antibody Expression Service Industry Opportunities and Challenges
  4. 2.4 Recombinant Antibody Expression Service Industry Restraints
3 Recombinant Antibody Expression Service Market by Company
  1. 3.1 Global Recombinant Antibody Expression Service Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Antibody Expression Service Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Antibody Expression Service Company Ranking (2024-2026)
  4. 3.4 Global Recombinant Antibody Expression Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Recombinant Antibody Expression Service Company Product Type and Application
  6. 3.6 Global Recombinant Antibody Expression Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Recombinant Antibody Expression Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Recombinant Antibody Expression Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Recombinant Antibody Expression Service Market by Type
  1. 4.1 Recombinant Antibody Expression Service Type Introduction
  2. 4.1.1 Recombinant Protein Mammalian Expression Service
  3. 4.1.2 Chimeric Antibody Expression Service
  4. 4.1.3 Recombinant Fragment Antibody Expression Service
  5. 4.1.4 VHH Nanobody Expression Service
  6. 4.2 Global Recombinant Antibody Expression Service Sales Value by Type
  7. 4.2.1 Global Recombinant Antibody Expression Service Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Recombinant Antibody Expression Service Sales Value by Type (2021-2032)
  9. 4.2.3 Global Recombinant Antibody Expression Service Sales Value Share by Type (2021-2032)
5 Recombinant Antibody Expression Service Market by Application
  1. 5.1 Recombinant Antibody Expression Service Application Introduction
  2. 5.1.1 Scientific Research
  3. 5.1.2 Immunodiagnostics
  4. 5.1.3 Antibody Drug Development
  5. 5.1.4 Others
  6. 5.2 Global Recombinant Antibody Expression Service Sales Value by Application
  7. 5.2.1 Global Recombinant Antibody Expression Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Recombinant Antibody Expression Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Recombinant Antibody Expression Service Sales Value Share by Application (2021-2032)
6 Recombinant Antibody Expression Service Regional Value Analysis
  1. 6.1 Global Recombinant Antibody Expression Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Antibody Expression Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Recombinant Antibody Expression Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Recombinant Antibody Expression Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Antibody Expression Service Sales Value (2021-2032)
  7. 6.3.2 North America Recombinant Antibody Expression Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Recombinant Antibody Expression Service Sales Value (2021-2032)
  10. 6.4.2 Europe Recombinant Antibody Expression Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Recombinant Antibody Expression Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Recombinant Antibody Expression Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Recombinant Antibody Expression Service Sales Value (2021-2032)
  16. 6.6.2 South America Recombinant Antibody Expression Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Recombinant Antibody Expression Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Recombinant Antibody Expression Service Sales Value Share by Country, 2025 VS 2032
7 Recombinant Antibody Expression Service Country-level Value Analysis
  1. 7.1 Global Recombinant Antibody Expression Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Antibody Expression Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Recombinant Antibody Expression Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Recombinant Antibody Expression Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Recombinant Antibody Expression Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Recombinant Antibody Expression Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Recombinant Antibody Expression Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GenScript Biotech
  2. 8.1.1 GenScript Biotech Company Information
  3. 8.1.2 GenScript Biotech Business Overview
  4. 8.1.3 GenScript Biotech Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GenScript Biotech Recombinant Antibody Expression Service Product Portfolio
  6. 8.1.5 GenScript Biotech Recent Developments
  7. 8.2 Creative Biolabs
  8. 8.2.1 Creative Biolabs Company Information
  9. 8.2.2 Creative Biolabs Business Overview
  10. 8.2.3 Creative Biolabs Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Creative Biolabs Recombinant Antibody Expression Service Product Portfolio
  12. 8.2.5 Creative Biolabs Recent Developments
  13. 8.3 Thermo Fisher Scientific
  14. 8.3.1 Thermo Fisher Scientific Company Information
  15. 8.3.2 Thermo Fisher Scientific Business Overview
  16. 8.3.3 Thermo Fisher Scientific Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Scientific Recombinant Antibody Expression Service Product Portfolio
  18. 8.3.5 Thermo Fisher Scientific Recent Developments
  19. 8.4 Bio-Rad Laboratories
  20. 8.4.1 Bio-Rad Laboratories Company Information
  21. 8.4.2 Bio-Rad Laboratories Business Overview
  22. 8.4.3 Bio-Rad Laboratories Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Rad Laboratories Recombinant Antibody Expression Service Product Portfolio
  24. 8.4.5 Bio-Rad Laboratories Recent Developments
  25. 8.5 Sino Biological
  26. 8.5.1 Sino Biological Company Information
  27. 8.5.2 Sino Biological Business Overview
  28. 8.5.3 Sino Biological Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sino Biological Recombinant Antibody Expression Service Product Portfolio
  30. 8.5.5 Sino Biological Recent Developments
  31. 8.6 ProMab Biotechnologies
  32. 8.6.1 ProMab Biotechnologies Company Information
  33. 8.6.2 ProMab Biotechnologies Business Overview
  34. 8.6.3 ProMab Biotechnologies Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProMab Biotechnologies Recombinant Antibody Expression Service Product Portfolio
  36. 8.6.5 ProMab Biotechnologies Recent Developments
  37. 8.7 LakePharma(Curia)
  38. 8.7.1 LakePharma(Curia) Company Information
  39. 8.7.2 LakePharma(Curia) Business Overview
  40. 8.7.3 LakePharma(Curia) Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 LakePharma(Curia) Recombinant Antibody Expression Service Product Portfolio
  42. 8.7.5 LakePharma(Curia) Recent Developments
  43. 8.8 Profacgen
  44. 8.8.1 Profacgen Company Information
  45. 8.8.2 Profacgen Business Overview
  46. 8.8.3 Profacgen Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Profacgen Recombinant Antibody Expression Service Product Portfolio
  48. 8.8.5 Profacgen Recent Developments
  49. 8.9 Atlas Antibodies
  50. 8.9.1 Atlas Antibodies Company Information
  51. 8.9.2 Atlas Antibodies Business Overview
  52. 8.9.3 Atlas Antibodies Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Atlas Antibodies Recombinant Antibody Expression Service Product Portfolio
  54. 8.9.5 Atlas Antibodies Recent Developments
  55. 8.10 Absolute Antibody
  56. 8.10.1 Absolute Antibody Company Information
  57. 8.10.2 Absolute Antibody Business Overview
  58. 8.10.3 Absolute Antibody Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Absolute Antibody Recombinant Antibody Expression Service Product Portfolio
  60. 8.10.5 Absolute Antibody Recent Developments
  61. 8.11 ProteoGenix
  62. 8.11.1 ProteoGenix Company Information
  63. 8.11.2 ProteoGenix Business Overview
  64. 8.11.3 ProteoGenix Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ProteoGenix Recombinant Antibody Expression Service Product Portfolio
  66. 8.11.5 ProteoGenix Recent Developments
  67. 8.12 Rockland Immunochemicals
  68. 8.12.1 Rockland Immunochemicals Company Information
  69. 8.12.2 Rockland Immunochemicals Business Overview
  70. 8.12.3 Rockland Immunochemicals Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Rockland Immunochemicals Recombinant Antibody Expression Service Product Portfolio
  72. 8.12.5 Rockland Immunochemicals Recent Developments
  73. 8.13 Proteintech
  74. 8.13.1 Proteintech Company Information
  75. 8.13.2 Proteintech Business Overview
  76. 8.13.3 Proteintech Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Proteintech Recombinant Antibody Expression Service Product Portfolio
  78. 8.13.5 Proteintech Recent Developments
  79. 8.14 RayBiotech
  80. 8.14.1 RayBiotech Company Information
  81. 8.14.2 RayBiotech Business Overview
  82. 8.14.3 RayBiotech Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 RayBiotech Recombinant Antibody Expression Service Product Portfolio
  84. 8.14.5 RayBiotech Recent Developments
  85. 8.15 BioLegend
  86. 8.15.1 BioLegend Company Information
  87. 8.15.2 BioLegend Business Overview
  88. 8.15.3 BioLegend Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BioLegend Recombinant Antibody Expression Service Product Portfolio
  90. 8.15.5 BioLegend Recent Developments
  91. 8.16 Agilent Technologies
  92. 8.16.1 Agilent Technologies Company Information
  93. 8.16.2 Agilent Technologies Business Overview
  94. 8.16.3 Agilent Technologies Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Agilent Technologies Recombinant Antibody Expression Service Product Portfolio
  96. 8.16.5 Agilent Technologies Recent Developments
  97. 8.17 Novus Biologicals
  98. 8.17.1 Novus Biologicals Company Information
  99. 8.17.2 Novus Biologicals Business Overview
  100. 8.17.3 Novus Biologicals Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novus Biologicals Recombinant Antibody Expression Service Product Portfolio
  102. 8.17.5 Novus Biologicals Recent Developments
  103. 8.18 OriGene Technologies
  104. 8.18.1 OriGene Technologies Company Information
  105. 8.18.2 OriGene Technologies Business Overview
  106. 8.18.3 OriGene Technologies Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 OriGene Technologies Recombinant Antibody Expression Service Product Portfolio
  108. 8.18.5 OriGene Technologies Recent Developments
  109. 8.19 ACROBiosystems
  110. 8.19.1 ACROBiosystems Company Information
  111. 8.19.2 ACROBiosystems Business Overview
  112. 8.19.3 ACROBiosystems Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  113. 8.19.4 ACROBiosystems Recombinant Antibody Expression Service Product Portfolio
  114. 8.19.5 ACROBiosystems Recent Developments
  115. 8.20 Fitzgerald Industries(Biosynth)
  116. 8.20.1 Fitzgerald Industries(Biosynth) Company Information
  117. 8.20.2 Fitzgerald Industries(Biosynth) Business Overview
  118. 8.20.3 Fitzgerald Industries(Biosynth) Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Fitzgerald Industries(Biosynth) Recombinant Antibody Expression Service Product Portfolio
  120. 8.20.5 Fitzgerald Industries(Biosynth) Recent Developments
  121. 8.21 Azenta Life Sciences
  122. 8.21.1 Azenta Life Sciences Company Information
  123. 8.21.2 Azenta Life Sciences Business Overview
  124. 8.21.3 Azenta Life Sciences Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Azenta Life Sciences Recombinant Antibody Expression Service Product Portfolio
  126. 8.21.5 Azenta Life Sciences Recent Developments
  127. 8.22 R&D Systems
  128. 8.22.1 R&D Systems Company Information
  129. 8.22.2 R&D Systems Business Overview
  130. 8.22.3 R&D Systems Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  131. 8.22.4 R&D Systems Recombinant Antibody Expression Service Product Portfolio
  132. 8.22.5 R&D Systems Recent Developments
  133. 8.23 Abnova
  134. 8.23.1 Abnova Company Information
  135. 8.23.2 Abnova Business Overview
  136. 8.23.3 Abnova Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Abnova Recombinant Antibody Expression Service Product Portfolio
  138. 8.23.5 Abnova Recent Developments
  139. 8.24 WuXi Biologics
  140. 8.24.1 WuXi Biologics Company Information
  141. 8.24.2 WuXi Biologics Business Overview
  142. 8.24.3 WuXi Biologics Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  143. 8.24.4 WuXi Biologics Recombinant Antibody Expression Service Product Portfolio
  144. 8.24.5 WuXi Biologics Recent Developments
  145. 8.25 Biointron Biological
  146. 8.25.1 Biointron Biological Company Information
  147. 8.25.2 Biointron Biological Business Overview
  148. 8.25.3 Biointron Biological Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Biointron Biological Recombinant Antibody Expression Service Product Portfolio
  150. 8.25.5 Biointron Biological Recent Developments
  151. 8.26 Detai Bio-Tech
  152. 8.26.1 Detai Bio-Tech Company Information
  153. 8.26.2 Detai Bio-Tech Business Overview
  154. 8.26.3 Detai Bio-Tech Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Detai Bio-Tech Recombinant Antibody Expression Service Product Portfolio
  156. 8.26.5 Detai Bio-Tech Recent Developments
  157. 8.27 cusabio
  158. 8.27.1 cusabio Company Information
  159. 8.27.2 cusabio Business Overview
  160. 8.27.3 cusabio Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  161. 8.27.4 cusabio Recombinant Antibody Expression Service Product Portfolio
  162. 8.27.5 cusabio Recent Developments
  163. 8.28 FITGENE
  164. 8.28.1 FITGENE Company Information
  165. 8.28.2 FITGENE Business Overview
  166. 8.28.3 FITGENE Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  167. 8.28.4 FITGENE Recombinant Antibody Expression Service Product Portfolio
  168. 8.28.5 FITGENE Recent Developments
  169. 8.29 GentleGen
  170. 8.29.1 GentleGen Company Information
  171. 8.29.2 GentleGen Business Overview
  172. 8.29.3 GentleGen Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  173. 8.29.4 GentleGen Recombinant Antibody Expression Service Product Portfolio
  174. 8.29.5 GentleGen Recent Developments
  175. 8.30 TekBiotech
  176. 8.30.1 TekBiotech Company Information
  177. 8.30.2 TekBiotech Business Overview
  178. 8.30.3 TekBiotech Recombinant Antibody Expression Service Revenue and Gross Margin (2021-2026)
  179. 8.30.4 TekBiotech Recombinant Antibody Expression Service Product Portfolio
  180. 8.30.5 TekBiotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst